Compare Novavax Inc (NVAX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Teucrium Wheat Fund — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Teucrium Wheat Fund trades at $24.41 (market cap $273.67M). The key difference: Novavax Inc is far larger — about 6.7× Teucrium Wheat Fund's market cap, and Novavax Inc is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Teucrium Wheat Fund for 40 Days on average.
| NVAX | WEAT | |
|---|---|---|
Market Cap | $1.82B | $273.67M |
Volume | 6,198,505 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $12.56 | $28.00 |
52-Week Low | $6.22 | $19.88 |
Typical Hold Time | 59 Days | 40 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
WEAT is trading at $24.41, down 1.97% with a bearish technical outlook as moving averages signal selling pressure. The wheat ETF faces mixed sentiment with recent price gains of 9.9% over the past month but current technical indicators showing weakness. Key support sits at $24 with resistance at $25, creating a tight trading range.
The ETF's performance remains tied to agricultural commodity volatility and inflation trends. Recent inflation data shows prices above Fed targets, potentially supporting commodity investments. However, technical weakness and the question of whether the recent rally is overdone present near-term challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
